Table 3.

Univariable and multivariable logistic regression analysis to evaluate whether FOLFOX is independently associated with near-pCR

Variable	Near-pCR		Univariable		Multivariable
	No (n=189)	Yes (n=120)	OR (95% CI)	P	OR (95% CI)	P
Induction group
CP	159 (67)	80 (33)	—		—
FOLFOX	30 (43)	40 (57)	2.65 (1.54 to 4.60)	<0.001	2.15 (1.17 to 4.00)	0.014
Age, years	65 (37 to 84)	64 (29 to 80)	1.0 (0.98 to 1.02)	0.89	1.0 (0.97 to 1.03)	0.98
Sex
Male	157 (60)	104 (40)	—		—
Female	32 (67)	16 (33)	0.75 (0.39 to 1.43)	0.40	0.62 (0.29 to 1.32)	0.22
Race
White	172 (62)	106 (38)	—		—
Other	17 (55)	14 (45)	1.34 (0.62 to 2.82)	0.45	1.34 (0.57 to 3.19)	0.50
Smoking status
Former/current	124 (61)	78 (39)			—
Never	65 (61)	42 (39)	1.03 (0.63 to 1.66)	0.91	1.15 (0.65 to 2.04)	0.63
Clinical T stage
cT1–2	22 (69)	10 (31)	—		—
cT3	158 (61)	101 (39)	1.41 (0.65 to 3.22)	0.40	1.87 (0.81 to 4.56)	0.15
cT4	9 (56)	7 (44)	1.71 (0.49 to 5.98)	0.40	1.66 (0.44 to 6.38)	0.45
Clinical N stage
cN0	53 (60)	35 (40)	—		—
cN+	136 (62)	85 (38)	0.95 (0.57 to 1.58)	0.83	0.72 (0.39 to 1.31)	0.28
Baseline grade
Poor	80 (59)	55 (41)	—		—
Well/moderate	107 (63)	63 (37)	0.86 (0.54 to 1.36)	0.51	0.76 (0.45 to 1.30)	0.32
LVI	64 (98)	1 (2)	0.02 (0.00 to 0.08)	<0.001	0.02 (0.00 to 0.08)	<0.001

Data are no. (row percentages) or median (range). Analysis was performed using a logistic regression model. The multivariable logistic regression analyses were adjusted for age, sex, race, smoking status, pretreatment histologic grade, clinical T and N stage, and vascular invasion. CI, confidence interval; CP, carboplatin plus paclitaxel; OR, odds ratio; LVI, lymphovascular invasion; pCR, pathologic complete response.